These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 3120733)

  • 1. Contributions of hippurate, indoxyl sulfate, and o-hydroxyhippurate to impaired ligand binding by plasma in azotemic humans.
    Gulyassy PF; Jarrard E; Stanfel LA
    Biochem Pharmacol; 1987 Dec; 36(24):4215-20. PubMed ID: 3120733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles of hippurate and indoxyl sulfate in the impaired ligand binding by azotemic plasma.
    Gulyassy PF; Jarrard E; Stanfel L
    Adv Exp Med Biol; 1987; 223():55-8. PubMed ID: 3128940
    [No Abstract]   [Full Text] [Related]  

  • 3. A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia.
    Lim CF; Bernard BF; de Jong M; Docter R; Krenning EP; Hennemann G
    J Clin Endocrinol Metab; 1993 Feb; 76(2):318-24. PubMed ID: 8432774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of the HEMO Study suggest that p-cresol sulfate and indoxyl sulfate are not associated with cardiovascular outcomes.
    Shafi T; Sirich TL; Meyer TW; Hostetter TH; Plummer NS; Hwang S; Melamed ML; Banerjee T; Coresh J; Powe NR
    Kidney Int; 2017 Dec; 92(6):1484-1492. PubMed ID: 28739139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Displacement by anionic drugs of endogenous ligands bound to albumin in uremic serum.
    Mabuchi H; Nakahashi H
    Ther Drug Monit; 1988; 10(3):261-4. PubMed ID: 3140432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accumulation of indoxyl sulfate, an inhibitor of drug-binding, in uremic serum as demonstrated by internal-surface reversed-phase liquid chromatography.
    Niwa T; Takeda N; Tatematsu A; Maeda K
    Clin Chem; 1988 Nov; 34(11):2264-7. PubMed ID: 3141084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of indoxyl sulfate in plasma of patients with renal failure by use of ion-pairing liquid chromatography.
    Stanfel LA; Gulyassy PF; Jarrard EA
    Clin Chem; 1986 Jun; 32(6):938-42. PubMed ID: 3085981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma hippurate in renal failure: high-performance liquid chromatography method and clinical application.
    Igarashi P; Gulyassy P; Stanfel L; Depner T
    Nephron; 1987; 47(4):290-4. PubMed ID: 3696332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The uremic toxin, indoxyl sulfate, signifies cardio-renal risk and intestinal-renal relationship].
    Kiss I
    Orv Hetil; 2011 Oct; 152(43):1724-30. PubMed ID: 21983398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolomic search for uremic toxins as indicators of the effect of an oral sorbent AST-120 by liquid chromatography/tandem mass spectrometry.
    Kikuchi K; Itoh Y; Tateoka R; Ezawa A; Murakami K; Niwa T
    J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Nov; 878(29):2997-3002. PubMed ID: 20870466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aromatic amino acid metabolites as potential protein binding inhibitors in human uremic plasma.
    Tavares-Almeida I; Gulyassy PF; Depner TA; Jarrard EA
    Biochem Pharmacol; 1985 Jul; 34(14):2431-8. PubMed ID: 4015686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients.
    Niwa T; Nomura T; Sugiyama S; Miyazaki T; Tsukushi S; Tsutsui S
    Kidney Int Suppl; 1997 Nov; 62():S23-8. PubMed ID: 9350673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prominent accumulation in hemodialysis patients of solutes normally cleared by tubular secretion.
    Sirich TL; Funk BA; Plummer NS; Hostetter TH; Meyer TW
    J Am Soc Nephrol; 2014 Mar; 25(3):615-22. PubMed ID: 24231664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profiling of endogenous ligand solutes that bind to serum proteins in sera of patients with uremia.
    Mabuchi H; Nakahashi H
    Nephron; 1986; 43(2):110-6. PubMed ID: 3086761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of salicylate binding to normal plasma by extracts of uremic fluids.
    Roman S; Gulyassy PF; Depner TA
    Am J Kidney Dis; 1984 Sep; 4(2):153-61. PubMed ID: 6475946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the oral adsorbent AST-120 on tryptophan metabolism in uremic patients.
    Tsubakihara Y; Takabatake Y; Oka K; Shoji T; Togawa M; Okada N; Takahito I; Imai E
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S38-41. PubMed ID: 12612950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Residual Function Effectively Controls Plasma Concentrations of Secreted Solutes in Patients on Twice Weekly Hemodialysis.
    Leong SC; Sao JN; Taussig A; Plummer NS; Meyer TW; Sirich TL
    J Am Soc Nephrol; 2018 Jul; 29(7):1992-1999. PubMed ID: 29728422
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effect of oral sorbent, AST-120, on serum concentration of indoxyl sulfate in uremic rats].
    Niwa T; Yazawa T; Maeda K; Ise M; Sugano M; Kodama T; Uehara Y
    Nihon Jinzo Gakkai Shi; 1990 Jun; 32(6):695-701. PubMed ID: 2120492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Albumin is the main plasma binding protein for indoxyl sulfate and p-cresyl sulfate.
    Viaene L; Annaert P; de Loor H; Poesen R; Evenepoel P; Meijers B
    Biopharm Drug Dispos; 2013 Apr; 34(3):165-75. PubMed ID: 23300093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppressed serum and urine levels of indoxyl sulfate by oral sorbent in experimental uremic rats.
    Niwa T; Miyazaki T; Hashimoto N; Hayashi H; Ise M; Uehara Y; Maeda K
    Am J Nephrol; 1992; 12(4):201-6. PubMed ID: 1481866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.